COMMUNIQUÉS West-GlobeNewswire

ASHA To Present Its Annie Glenn Award To The Pitt
06/08/2026
TV Medical Drama Spotlights the Importance of Effective Communication Rockville, MD, Aug. 06, 2026 (GLOBE NEWSWIRE) -- The Pitt , a popular and highly regarded TV series, will receive the American Speech-Language- [...]
Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results
06/08/2026
Press Release – No. 14 / 2026 Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results Copenhagen, Denmark, August 6, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) ( [...]
Genmab Announces Financial Results for the First Half of 2026
06/08/2026
August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory [...]
Chemed Corporation Declares Quarterly Dividend of 70 Cents
06/08/2026
CINCINNATI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE ) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, [...]
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
06/08/2026
First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor support Analysis of blood and lung fluid showed [...]
Maxim Hair Restoration Earns LegitScript Certification, Reinforcing Its Position as a Leading Hair Transplant Clinic
06/08/2026
Certification underscores Maxim's commitment to ethical and transparent practices in hair restoration services. New York City, NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Maxim Hair Restoration , a 15-location [...]
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
06/08/2026
Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc [...]
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
06/08/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; [...]
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable [...]
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
06/08/2026
ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast [...]
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to [...]
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
06/08/2026
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the [...]
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
06/08/2026
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 ™ trial is a Phase 1, randomized, controlled clinical trial design to characterize [...]
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
06/08/2026
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to [...]
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
06/08/2026
- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) - - Study builds on [...]
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
06/08/2026
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome measures showed [...]
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
06/08/2026
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46 th Annual Growth Conference on Tuesday, [...]
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
06/08/2026
TransCon ® CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growth TransCon CNP monotherapy Week 104 data from the [...]

Pages